CLINICAL CASE REPORT: HEAD AND NECK RHABOMATOSIS IN CHILDREN – A CASE OF MULTI-MODAL TREATMENT
Main Article Content
Abstract
Case introduction: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents, with approximately 35% arising in the head and neck region. Treatment is particularly challenging due to the risk of damage to the complex anatomy and functional impairment within the head and neck area. Moreover, high-risk RMS pediatric patients have a poor prognosis. We present a case of an 11-year-old female patient diagnosed with high-risk RMS of the left nasal cavity. The patient underwent a primary surgical procedure. Unfortunately, the patient had early progression of localized disease during treatment with IVADo chemotherapy regimen. After multidisciplinary tumor board discussion, the patient received multimodality therapy with definitive radiotherapy and chemotherapy. Recently, the child has remained disease-free, without complications of treatment at 23 months of follow-up. Conclusion: The management of high-risk head and neck RMS in children emphasizes the importance of individualized, multimodality approaches to optimize disease control and preserve organ function.
Keywords
Rhabdomyosarcoma, head and neck, children, multimodal treatment
Article Details
References
2. Bisogno G, De Salvo GL, Bergeron C, et al. Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Journal of Clinical Oncology. 2018;36(18_suppl).
3. Yang P, Grufferman S, Khoury MJ, et al. Association of childhood rhabdomyosarcoma with neurofibromatosis type I and birth defects. Genet Epidemiol. 1995;12(5):467-74
4. Linardic CM, Wexler LH: Rhabdomyosarcoma: Epidemiology and Genetic Susceptibility. Pizzo and Poplack's Pediatric Oncology, tái bản lần thứ 8, 2021, trang 693
5. PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Rhabdomyosarcoma Treatment. Bethesda, MD: National Cancer Institute. Updated: 04/11/2025. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/rhabdomyosarcoma-treatment-pdq. Accessed: 08/18/2025.
6. Rodeberg D, Paidas C. Childhood rhabdomyosarcoma. Semin Pediatr Surg. 2006;15(1):57-62.
7. Nghiêm Ngọc Linh. Nhận xét kết quả điều trị sarcom cơ vân trẻ em. Đại học y Hà Nội (2018)
8. Merks JHM, Brack E, Ebinger M, et al. European standard clinical practice recommendations for children and adolescents with Rhabdomyosarcoma a joint EpSSG, CWS and ERN PaedCan project. EJC Paediatric Oncology. 2025; 5.
9. Glosli H, Bisogno G, Kelsey A, et al. Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) - RMS2005 study. Eur J Cancer. 2021;151:84-93
10. Haduong JH, Heske CM, Allen-Rhoades W, et al. An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials. Pediatr Blood Cancer. 2022; 69(4):e29511.
11. Lockney NA, Friedman DN, Wexler LH, et al. Late Toxicities of Intensity-Modulated Radiation Therapy for Head and Neck Rhabdomyosarcoma. Pediatr Blood Cancer. 2016; 63(9):1608-14.